Nexien BioPharma Inc (NXEN)

[High_Profits]

$NTVA CEO (VIDEO)
What Does Repeal of Cole Memorandum Mean for Legal Cannabis Industry?

In this episode of CannexVentures we talk to Intiva BioPharma CEO & Cannabis Entrepreneur, Jeff Friedland about the recent move by US Attorney General, Jeff Sessions to roll back the Cole Memorandum.

Put in place during the Obama Administration by then Deputy Attorney General, James Cole, the memorandum indicated that prosecutors and law enforcement should focus only on the following priorities related to state-legal cannabis operations:

1. Preventing the distribution of marijuana to minors;
2. Preventing revenue from the sale of marijuana from going to criminal enterprises, gangs and cartels;
3. Preventing the diversion of marijuana from states where it is legal under state law in some form to other states;
4. Preventing state-authorized marijuana activity from being used as a cover or pretext for the trafficking of other illegal drugs or other illegal activity;
5. Preventing violence and the use of firearms in the cultivation and distribution of marijuana;
6. Preventing drugged driving and the exacerbation of other adverse public health consequences associated with marijuana use;
7. Preventing the growing of marijuana on public lands and the attendant public safety and environmental dangers posed by marijuana production on public lands; and
8. Preventing marijuana possession or use on federal property.

Mr. Friedland is also currently CEO of Intiva BioPharma, Inc. (NTVA)

INTIVA BioPharma Inc. ("INTIVA”) is pursuing the formulation of cannabinoid-based drugs for various medical conditions and disorders, all under U.S. Food and Drug Administration (FDA) development pathways.

?ArcView Market Research estimates that America's pharmaceutical cannabis sector could reach over $23 billion by 2020. Research published by New Frontier Data indicates that the United States constitutes 35% of the global pharmaceutical market, the largest market in the world, and a major driver of the U.S. economy. New Frontier has indicated that cannabinoid-derived drugs and related products could replace $4.4 to $4.9 billion annually spent on existing treatments.